Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

A new digital wound care module assists clinicians in selecting appropriate dressings and generating standardized treatment ...

DUBLIN--(BUSINESS WIRE)--The "Intermittent Claudication - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Summary The latest Pharmaceutical and Healthcare ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease, the use of alternative pain-free exercise methods may be ...

DUBLIN--(BUSINESS WIRE)--The "2018 Intermittent Claudication Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Intermittent Claudication Market" ...

(UPDATED) The biggest gains in walking distance among patients with intermittent claudication are seen with the combined use of angioplasty and supervised exercise therapy on top of best medical ...

For the IRONIC trial, investigators led by Joakim Nordanstig, MD, PhD, of Sahlgrenska University Hospital (Gothenburg, Sweden), randomized 158 patients with stable intermittent claudication to ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...

Dr. Rob Riley joins us each week from the South Bend Clinic. Here are his responses from April 2. Linda: What is intermittent claudication? Intermittent claudication is a symptom that occurs in people ...

HAIFA, Israel, Jan. 18, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced the successful completion of a parallel scientific advisory process with the ...